- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 13, 2025
Management Tracks
Lee joins Lycia as CMO
Plus: Firth joins Panacea, Lakewood appoints Manion chair and updates from Ai Proteins, Cognito and Kala
BioCentury | Jan 29, 2025
Guest Commentary
Winning over Wall Street: Biotechs’ comeback playbook — a Guest Commentary by Jami Rubin
Advice for CEOs and CFOs as they navigate the year ahead
BioCentury | Dec 31, 2024
Finance
Biotech raises make 2024 the year of the PIPE
BioCentury’s final Public Equity Report of the year tallies up fundraising activity
BioCentury | May 3, 2024
Discovery & Translation
CAR T cells: Cancer, autoimmunity, and beyond?
ASGCT abstracts highlight applications for CAR Ts outside of cancer
BioCentury | May 2, 2024
Management Tracks
McDonnell now CEO of Agilent
Plus: Dubensky to lead ImmuneSensor and updates from NORD and Epsilogen
BioCentury | Apr 23, 2024
Deals
Incyte’s hopes for mast cell program spur $750M Escient takeout
Deal gives Incyte clinical molecules for inflammatory, dermatological disorders
BioCentury | Oct 25, 2023
Emerging Company Profile
Aiolos: going for best in class with a long-acting TSLP mAb for asthma
Start-up, which launched with a $245M series A, is taking on AstraZeneca-Amgen drug with a mAb in-licensed from China-based Hengrui
BioCentury | Feb 9, 2023
Product Development
Feb. 8 Quick Takes: Galapagos slides on Phase III miss for filgotinib in Crohn’s
Plus: CureVac prices upsized $250M follow-on and updates from Novartis, UCB, TVM Capital and more
BioCentury | Feb 7, 2023
Product Development
Feb. 6 Quick Takes: Idorsia falls on Phase III miss
Plus: Arrowhead awaits J&J’s decision on HBV partnership and updates from Dragonfly, Sage-Biogen, IgGenix, Certa and more
Items per page:
1 - 10 of 421